Myriad Genetics (LTS:0K3W) Construction In Progress : $0.0 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Myriad Genetics Construction In Progress?

Myriad Genetics Construction In Progress Historical Data

The historical data trend for Myriad Genetics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Construction In Progress Chart

Myriad Genetics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

Myriad Genetics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

Myriad Genetics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Myriad Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (LTS:0K3W) » Definitions » Construction In Progress

Comparable Companies

CDNA OPK CSTL NEO GRAL FLGT TWST ACRS ATLN PSNL TMO DHR XSWX:LONN A IQV IDXX MTD ILMN WAT NTRA

Traded in Other Exchanges

MYGN:USA MYD:Germany MYD:Germany MYD:Germany

Address

320 Wakara Way, Salt Lake City, UT, USA, 84108

Website

https://www.myriad.com

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Myriad Genetics Headlines

No Headlines